Skip to Page Content

FREE PREVIEW | Subscribers get full access to this article:   Free Trial »   Subscribe »

The Pink Sheet

Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent


Executive Summary

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.


Purchase this Article

$85.00   Buy Now


For $85.00, purchase this 2497-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Log In


Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.